ONMDW · OneMedNet Corp
Substantial doubt about the company's ability to continue as a going concern.
“The Company's cash balance of $0.4 million is not adequate to fund its operations through at least twelve months from the date these condensed consolidated financial statements were available for issuance. Therefore, these conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score Cluster buy
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-30 | Kosasa Thomas |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
On July 30, 2026, the issuer entered into a subscription agreement with the reporting person for a $1,000,000 investment in the issuer. The shares were valued at the volume-weighted average price (VWAP) of the issuer for the 10 trading days immediately prior to the purchase date. |
Common Stock
|
1,449,275 |
| 2026-06-23 | Green Aaron |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
Represents an open market purchase in a single transaction. |
Common Stock
|
36,650 |
| 2026-06-23 | Yu Jeffrey |
Director, Chief Medical Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
On June 23, 2026, the issuer entered into a subscription agreement with the reporting person for a $100,000 investment in the issuer. |
Common Stock
|
158,730 |
| 2026-06-16 | Yu Jeffrey |
Director, Chief Medical Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
On June 16, 2026, the issuer entered into a subscription agreement with the reporting person for a $100,000 investment in the issuer. |
Common Stock
|
172,414 |
| 2026-06-15 | Green Aaron |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
18,702 |
| 2026-06-12 | Kosasa Thomas |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
On June 12, 2026, the issuer entered into a subscription agreement with the reporting person for a $100,000 investment in the issuer. The shares were valued at the volume-weighted average price (VWAP) of the issuer for the 10 trading days immediately prior to the purchase date. |
Common Stock
|
158,730 |
| 2026-06-12 | Green Aaron |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.5463 to $0.5625, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in the footnotes of this report. |
Common Stock
|
36,920 |
| 2026-05-18 | Kosasa Thomas |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
On May 18, 2026, the issuer entered into a subscription agreement with the reporting person for a $250,000 investment in the issuer. The shares were valued at the volume-weighted average price (VWAP) of the issuer for the 10 trading days immediately prior to the purchase date. |
Common Stock
|
268,817 |
| 2026-04-23 | Kosasa Thomas |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
On April 23, 2026, the issuer entered into a subscription agreement with the reporting person for a $250,000 investment in the issuer. The shares were valued at the volume-weighted average price for the 10 trading days immediately prior to the applicable purchase date. |
Common Stock
|
280,898 |
| 2026-04-01 | Yu Jeffrey |
Director, Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares issued in lieu of prior cash compensation owed to the reporting person. The shares were valued at the volume-weighted average price for the 10 trading days immediately prior to the issuance date. |
Common Stock
|
219,429 |
| 2026-04-01 | Yu Jeffrey |
Director, Chief Medical Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
On April 1, 2026, the issuer entered into a subscription agreement with the reporting person for a $750,000 investment in the issuer. The shares were valued at the volume-weighted average price for the 10 trading days immediately prior to the purchase date. |
Common Stock
|
903,614 |
| 2026-02-06 | Kosasa Thomas |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
On February 6, 2026, the issuer entered into a subscription agreement with the reporting person for a $500,000 investment in the issuer. The shares were valued at the volume-weighted average price for the 10 trading days immediately prior to the applicable purchase date. |
Common Stock
|
595,238 |
| 2025-11-26 | Clarke Jair |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents RSUs granted as director compensation under the 2022 Plan for board service in fiscal year 2025. The RSUs vest on December 31, 2025, subject to the reporting person's continued service with the issuer through the vesting date. |
Common Stock
|
45,000 |
| 2025-11-26 | Alleyne Kenneth |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs") granted as director compensation under the OneMedNet Corporation 2022 Equity Incentive Plan for board service in fiscal year 2025. Each RSU represents the contingent right to receive one share of the issuer's common stock. The RSUs vest on December 31, 2025, subject to the reporting person's continued service with the issuer through the vesting date. |
Common Stock
|
38,219 |
| 2025-11-26 | Kosasa Thomas |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents RSUs granted as director compensation under the 2022 Plan for board service in fiscal year 2025. The RSUs vest on December 31, 2025, subject to the reporting person's continued service with the issuer through the vesting date. |
Common Stock
|
45,000 |
| 2025-11-26 | Zeinfeld Andrew B |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents RSUs granted as director compensation under the 2022 Plan for board service in fiscal year 2025. The RSUs vest on December 31, 2025, subject to the reporting person's continued service with the issuer through the vesting date. |
Common Stock
|
45,000 |
| 2025-11-26 | Golden Robert Lawrence |
Director, Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents RSUs granted as director compensation under the 2022 Plan for board service in fiscal year 2025. The RSUs vest on December 31, 2025, subject to the reporting person's continued service with the issuer through the vesting date. |
Common Stock
|
45,000 |
| 2025-11-26 | Yu Jeffrey |
Director, Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents RSUs granted as director compensation under the 2022 Plan for board service in fiscal year 2025. The RSUs vest on December 31, 2025, subject to the reporting person's continued service with the issuer through the vesting date. |
Common Stock
|
45,000 |
| 2025-11-26 | Green Aaron |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents RSUs granted as director compensation under the 2022 Plan for board service in fiscal year 2025. The RSUs vest on December 31, 2025, subject to the reporting person's continued service with the issuer through the vesting date. |
Common Stock
|
45,000 |
| 2025-11-26 | McCraw Sherry Coonse |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents RSUs granted as director compensation under the 2022 Plan for board service in fiscal year 2025. The RSUs vest on December 31, 2025, subject to the reporting person's continued service with the issuer through the vesting date. |
Common Stock
|
45,000 |
| 2025-11-26 | Casaburi Eric |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents RSUs granted as director compensation under the 2022 Plan for board service in fiscal year 2025. The RSUs vest on December 31, 2025, subject to the reporting person's continued service with the issuer through the vesting date. |
Common Stock
|
45,000 |
| 2025-11-24 | Golden Robert Lawrence |
Director, Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents RSUs granted pursuant to contractor arrangements with the reporting person. The RSUs vest with respect to 1/3 of the shares on the first anniversary of the vesting start date of January 1, 2025, with the remaining RSUs vesting in equal quarterly installments on the last day of each fiscal quarter over 24 months thereafter, subject to the reporting person's continued service with the issuer through each vesting date. |
Common Stock
|
300,000 |
| 2025-11-24 | Green Aaron |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents RSUs granted under the 2022 Plan as employment compensation for fiscal years 2024 and 2025. The RSUs vest with respect to 47% of the RSUs on the first anniversary of the vesting start date of January 1, 2025, with the remaining RSUs vesting on the last day of each fiscal quarter as follows: (i) 33% of the RSUs in equal quarterly installment during fiscal year 2026, and (ii) 20% of the RSUs in equal quarterly installment during fiscal year 2027, subject to the reporting person's continued service with the issuer through each vesting date. |
Common Stock
|
1,000,000 |
| 2025-11-24 | Golden Robert Lawrence |
Director, Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents RSUs granted pursuant to contractor arrangements with the reporting person. The RSUs vest in full on December 31, 2025, subject to the terms of Section 7.2.2 of the Consulting Agreement, dated August 30, 2024, between the issuer and Mr. Golden. |
Common Stock
|
33,333 |
| 2025-11-24 | Yu Jeffrey |
Director, Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs") granted under the OneMedNet Corporation 2022 Equity Incentive Plan (the "2022 Plan") as employment compensation. RSUs vest as to one-third (1/3) of the RSUs on the first anniversary of the vesting start date of January 1, 2025, with the remaining RSUs vesting thereafter in equal quarterly installments on the last day of each fiscal quarter over the subsequent two (2) years, provided that the recipient remains in continuous service through each vesting date. |
Common Stock
|
200,000 |
| 2025-11-18 | Green Aaron |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold solely to cover tax withholding obligations upon vesting and settlement of restricted stock unit awards. |
Common Stock
|
61,555 |
| 2025-10-22 | Green Aaron |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold solely to cover tax withholding obligations upon vesting and settlement of restricted stock unit awards. |
Common Stock
|
64,767 |
| 2025-10-15 | Casaburi Eric |
Director |
Buy↑
|
Common Stock
|
10,000 |
| 2025-09-25 | Yu Jeffrey |
Director, Chief Medical Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.03 to $1.04, inclusive. |
Common Stock
|
1,250 |
| 2025-09-24 | Yu Jeffrey |
Director, Chief Medical Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.01 to $1.05, inclusive. |
Common Stock
|
17,200 |
| 2025-09-24 | Kosasa Thomas |
Director |
Buy↑
|
Common Stock
|
6,000 |
| 2025-09-23 | Yu Jeffrey |
Director, Chief Medical Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.91 to $0.96, inclusive. |
Common Stock
|
5,700 |
| 2025-09-22 | Yu Jeffrey |
Director, Chief Medical Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.93 to $0.99, inclusive. |
Common Stock
|
400 |
| 2025-09-19 | Yu Jeffrey |
Director, Chief Medical Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.88 to $0.92, inclusive. |
Common Stock
|
1,250 |
| 2025-09-18 | Yu Jeffrey |
Director, Chief Medical Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.89 to $0.94, inclusive. |
Common Stock
|
700 |
| 2025-09-05 | Yu Jeffrey |
Director, Chief Medical Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.84 to $0.90, inclusive. |
Common Stock
|
2,100 |
| 2025-09-04 | Yu Jeffrey |
Director, Chief Medical Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.84 to $0.92, inclusive. |
Common Stock
|
11,810 |
| 2025-09-03 | Yu Jeffrey |
Director, Chief Medical Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.77 to $0.86, inclusive. |
Common Stock
|
11,670 |
| 2025-09-02 | Yu Jeffrey |
Director, Chief Medical Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.83 to $0.88, inclusive. |
Common Stock
|
24,319 |
| 2025-08-29 | Yu Jeffrey |
Director, Chief Medical Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.79 to $0.85, inclusive. |
Common Stock
|
10,890 |
| 2025-08-29 | Kosasa Thomas |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
On August 29, 2025, the issuer entered into a subscription agreement with the reporting person, pursuant to which the issuer agreed to sell 581,395 shares of common stock to the reporting person at a purchase price of $0.86 per share, totaling $500,000 in gross proceeds to the issuer. |
Common Stock
|
581,395 |
| 2025-08-28 | Yu Jeffrey |
Director, Chief Medical Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.78 to $0.81, inclusive. |
Common Stock
|
17,000 |
| 2025-08-27 | Yu Jeffrey |
Director, Chief Medical Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.68 to $0.72, inclusive. |
Common Stock
|
21,374 |
| 2025-08-26 | Yu Jeffrey |
Director, Chief Medical Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.66 to $0.79, inclusive. |
Common Stock
|
173,350 |
| 2025-08-25 | Yu Jeffrey |
Director, Chief Medical Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.74 to $0.75, inclusive. |
Common Stock
|
13,300 |
| 2025-08-21 | Yu Jeffrey |
Director, Chief Medical Officer |
Buy↑
|
Common Stock
|
15,000 |
| 2025-08-19 | Yu Jeffrey |
Director, Chief Medical Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.76 to $0.79, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in the footnotes of this report. |
Common Stock
|
16,500 |
| 2025-06-20 | Kosasa Thomas |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
On June 20, 2025, the issuer entered into a subscription agreement with the reporting person, pursuant which the issuer agreed to sell 1,190,476 shares of common stock to the reporting person at a purchase price of $0.42 per share, totaling $500,000 in gross proceeds to the issuer. |
Common Stock
|
1,190,476 |
| 2025-06-20 | Yu Jeffrey |
Director, Chief Medical Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
On June 20, 2025, the issuer entered into a subscription agreement with the reporting person, pursuant which the issuer agreed to sell 1,666,666 shares of common stock to the reporting person at a purchase price of $0.42 per share, totaling $700,000 in gross proceeds to the issuer. |
Common Stock
|
1,666,666 |
| 2025-06-19 | Kosasa Thomas |
Director |
Other↑
Filing footnotes — Common Stock (Direct)
On June 19, 2025, the reporting person delivered notice of his election to convert in full the amounts of outstanding principal under certain convertible shareholder loans previously made by the reporting person to the issuer, in an aggregate principal amount of approximately $1.6 million. |
Common Stock
|
2,123,424 |